🔗 Share this article

As the United States continues making sweeping changes to its vaccine guidelines, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots in the pandemic and has focused upon alleged fatalities after Covid immunization in her short time at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Public health authorities were set to unveil major changes to the pediatric immunization program recently, bringing the US with Denmark’s immunization schedule, according to reports – a major change that would place the US out of alignment with many the world with no evidence for public health gain. The announcement has been postponed until the next year.

In place of the top vaccines chief, Høeg is listed to present at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to head the center this year.

Consolidating Power at the FDA

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon rolling back long-standing immunizations at the FDA.

Høeg has frequently advocated for halting certain pediatric shot schedules in the US so as to align more like Denmark, a society with nationalized medicine and a population about the size of Wisconsin’s.

To date public appearances, she has kept her attention on vaccination policy – usually the purview of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no apparent experience in medication creation, regulation or management, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Former heads of CBER would “understand regulatory frameworks and the research of drug development”, said Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that previous people who led CBER have had.”

The drug center has an immense portfolio at the FDA, Woodcock emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic program authorizes numerous generic medications. There’s a biosimilars program, non-prescription drug unit and more, and all of those have to be looked after,” Dr. Woodcock explained. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership component to the position, which supervises over 5,000 employees. “It’s a massive management job, if you perform it correctly,” the former official added.

Official Statement and Controversial Policies

In response to inquiries about Høeg’s fitness for the role and whether this assignment represents increased cooperation among agency officials on immunizations, a representative said that the “questions are based on incorrect premises”.

“This background aligns with the duties of her position,” the official explained, citing the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid therapy clearance system that allegedly concerned her preceding directors. “How are these drugs being picked for this expedited pathway? Who makes the calls?” Dr. Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

Overall, he stated, “the FDA seems to be moving towards less stringent regulations of most medications, except for vaccines.”

Public Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if concerning, track record, some experts said. She authored a analysis using unverified crowd-sourced reports to estimate the incidence of heart inflammation after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the new government included changing guidelines for recently developed shots and discontinuing “unnecessary” immunizations, she said following the vote on a podcast. At the FDA, Dr. Høeg has according to sources suggested barring teenage boys from getting Covid vaccines.

“She is an complete true believer who starts off with her beliefs and works backwards to fit the data in a highly deceptive, dishonest fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|